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Abstract 
Small  cell  carcinoma  (SCC)  or  microcytic
carcinoma of the urinary bladder is a rare enti-
ty comprising approximately 0.5% of all bladder
tumors. Due to its rarity, no prospective stud-
ies  evaluating  the  most  effective  treatment
have been published in the medical literature.
Several cases of bladder SCC have been pre-
sented so far. We describe our case report and
we  revise  the  recent  literature.  Our  patient
was diagnosed with pure bladder SCC and pro-
static  adenocarcinoma.  After  the  initial  and
complete transurethral resection of the blad-
der tumour (TUR-BT), he underwent a thorax
and mediastinum computer tomography (CT)
examination  to  exclude  primary  pulmonary
small cell carcinoma and a bone scan scintigra-
phy for staging purposes. He received a three
14-day cycles of Cisplatin-containing chemo  -
therapeutic  schema  and  a  single  dose  of
Luteinizing-Hormone  Releasing  hormone
(LHRH)  analogue  injection  after  14  days  of
bicalutamide  administration.  The  patient  is
followed for 24 months without any signs of
bladder SCC recurrence or biochemical or local
relapse from prostatic adenocarcinoma. 
Introduction
Small  cell  carcinoma  (SCC)  or  microcytic
carcinoma of the urinary bladder is a rare enti-
ty comprising approximately 0.5% of all bladder
tumors. It belongs to the group of neuroen-
docrine tumors and shares many characteris-
tics with its pulmonary counterpart in respect
of aggressiveness, invasiveness and poor prog-
nosis. Because of the rarity of the disease, no
prospective studies evaluating the most effec-
tive treatment have been done. Several cases
of bladder SCC have been presented so far but
this is the first time that a synchronous pure
microcytic  bladder  carcinoma  and  prostate
adenocarcinoma  case  report  is  published,
according  to  medical  literature  searching  in
PubMed. We describe our case report and the
recent literature is revised.
Case Report
A 72-years-old man, non-smoker, presented
to our emergency department due to urinary
retention. He had a 2-day history of painless
gross hematuria. Four years ago he had been
treated  for  a  stage  T1,  high-grade  papillary
urothelial carcinoma, with transurethral resec-
tion of the bladder tumor (TUR-BT) and he
received  a  program  of  bacillus  Calmette-
Guerin (BCG) instillations for 12 months. Past
medical history included arterial hypertension
and hyperlipidemia under per Os (PO) medica-
tion  and  appendicectomy  in  childhood.  The
physical  examination  revealed  a  tender
hypogastrium  on  palpation  and  dullness  on
percussion.  Ultrasonographically,  the  bladder
was overdistended with more than 800 ml of
fluid and a large isoechoic mass was observed.
A three-way catheter was inserted to evacuate
the hollow organ from urine and blood clots,
flushing  and  continuous  bladder  irrigation
installed.  Digital  rectal  examination  (DRE)
recognized a palpable hard nodular mass at the
prostate’s base at the right lobe, in an other-
wise normal prostate gland.
Laboratory test results were within normal
limits except for a hemoglobin concentration
(Hb)  of  8.1  g/dL  and  a  white  blood  count
(WBC)  of  13ﾥ109/L.  Renal  function  tests
showed  slight  elevation  creatinine  and  urea
without  electrolytic  disturbances  and  the
glomerular filtration rate (GFR) was estimated
85  mL/min/1.73  m2.  A  three  weeks  before
Prostatic specific antigen (PSA) examination
was 1.83 ng/mL and a 6-month before meas-
urement  was  2.01  ng/mL.  The  patient  was
admitted to the Urology department for further
evaluation and treatment.  
On the next day, the patient underwent a
multiphase helical computer tomography (CT)
examination of the abdomen and pelvis with a
multidetector scanner prior and after adminis-
tration  of  PO  and  Intravenous  (IV)  contrast
material. A late scanning phase was included
in the study. A mass was seen on the base to
the left lateral wall of the urinary bladder 5 cm
in  diameter,  with  filling  defect  and  possible
extension to prostate and to perivesicular fat
(Figure 1). Additionally, a mild hydrocalicosis
of  the  left  pelvicocalyceal  system  was  diag-
nosed and a 4 cm parapyelic cyst on the right
kidney was seen without any clinical signifi-
cance, category I according to Bosniak classifi-
cation  system.  There  was  no  distinct  lymph
node involvement neither on deep retroperi-
toneal nor on superficial pelvic and inguinal
regions as well as no involvement of parenchy-
mal organs such as liver, spleen, pancreas and
adrenals. 
Subsequently,  we  decided  to  evaluate  the
patient in the operating theater. Under spinal
anesthesia  a  bimanual  bladder  examination
took  place  that  showed  a  non-fixed  mobile
bladder. The CT findings were confirmed by
rigid urethrocystoscopy. A large based lesion
was observed from the bladder neck to the mid-
dle of bladder posterior wall from the midline
to the upper third of the left lateral wall while
the urethra including prostatic part were free
of papillary lesions except of small lesion rec-
ognized anteriorly of the bladder neck at 4 o
clock position. Typical TUR-BT followed includ-
ing resection of the entire visible tumor mass
and  multiple  random  bladder  biopsies  were
obtained from the healthy looking bladder wall
and prostatic urethra. Random biopsy speci-
mens were placed in a separate tissue boxes
for  tumor  mapping  purposes.1 Due  to  the
abnormal  DRE  findings,  sextant  transrectal
ultrasonographic  (TRUS)  guided  prostate
biopsy followed the tumor resection, using a
portable 8MHz probe carrying TRUS device.
The  surgical  specimen  after  TUR-BT,
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plete invasion by malignant neoplasm which
was  consisted  of  small  uniform  cells,  with
undiscerning boundaries, slightly eosinophilic
cytoplasm, big spherical and polygonic nuclei
tiny nucleolus and spotty distribution of chro-
matin. Mitotic activity was abundant but atypi-
cal (Figure 2). Immunohistochemistry reveal
possitiveness of the neoplastic cells to Neuron
specific enolase (NSE) antibody staining pro-
tocol and Cytokine Human interleukin 7 (Cyt7)
and focally positiveness to CD56, while it was
negative in Leukocyte common Antigen (LCA)
and Cytokine Human interleukin 20 (Cyt20)
resembling  the  pure  small  cell  (microcytic)
carcinoma (SCC), without recognition of tran-
sitional  carcinoma  cellular  pattern.  Normal
urothelium was recognized in the specimens
after  random  biopsy  and  the  chips  from
prostate gland showed adenomatous hyperpla-
sia and marked invasions from the microcytic
carcinoma (Figure 3).
The  12  pieces  prostate  biopsy  core  tissue
was examined microscopically.  Two out of six
right lobe cores found to be occupied at 25-30%
by prostatic adenocarcinoma Gleason 6(3+3).
Postoperatively, hematuria subsided and the
catheter was removed at the 3rd postoperative
day. Although the chest X-ray was negative for
neoplastic  lung  lesions,  a  thorax  CT  was
ordered to exclude primary pulmonary small
cell carcinoma. The CT was negative. For stag-
ing  purposed  the  patient  underwent  a  bone
scan scintigraphy with technetium 99m (Tc-
99m), in HDP type, 750 MBq. There were no
lesions of metastasis but some degenerative
lesions were observed.
Using  the  TNM  classification  based  on
European  Urology  guidelines  2009,  the  neo-
plasm was staged as T4a, N0, M0. Based on the
TNM,  patient  performance  status  (PS)  as
assessed by Karnofsky scale and patient’s few
co morbidities radical cystoprostatectomy was
offered as a potential radical treatment.2,3 The
patient nevertheless refused this recommen-
dation  and  a  less  radical  therapy  including
adjuvant chemotherapy and androgenic block-
age were offered as a second option.
After interdisciplinary consultation, bimodal
treatment was given with chemotherapy and
complete androgenic blockage. An antiandro-
gen bicalutamide 50mg/day started immediate-
ly and a single dose of Luteinizing-Hormone
releasing  hormone  (LHRH)  analogue  was
given after 14 days. Based on De Santis et al.
criteria the patient was defined as fit, with a
GFR>60 mL/min and a PS 0-1, and he planed
for  administration  of  Cisplatin-containing
combination  chemotherapy.4,5 The  patient
received three 14-day cycles of Methotrexate
30  mg/m2 IV,  Vinblastine  3  mg/m2 IV,  Doxo -
rubicin 30 mg/m2 IV and Cisplatin 70 mg/m2 IV
(MVAC) as proposed by Bamias et al.6 There
were only mild side effects that were managed
supportingly such as nausea, indigestion, loss
of appetite and peripheral neuropathy experi-
enced mostly around the ankles as numbness.
A follow up took place at the 2ndmonth after the
initial resection. Blood count reveals an ane-
mic (Hb: 9.5 mg/dL), mild leucopenic (WBC:
3.5ﾥ109/L)  and  slightly  thrombopenic    (Plt:
90ﾥ106/L) patient. The PSA was in near castra-
tion levels (PSA: 0.19 ng/mL). He underwent a
second TUR for random biopsy purposes that
were histologically and immunohistocemically
negative. The next trimester we discontinued
the antiandrogens since the PSA was kept at
castration levels (PSA: 0.01 ng/mL, as a part of
intermittent androgenic blockage therapy and
he is still under regular follow up by flexible
cystoscopy every 3 months, PSA measurement
and CT of thorax, abdomen and pelvis every 6
months. The patient is still alive and in good
health, after 24 months from the initial diagno-
sis.
Discussion
Extra pulmonary SCC is a rare but well-char-
acterized entity.7 It has been described in sev-
eral  organs  including  gastrointestinal,  geni-
tourinary, skin etc.8-14 The SCC of the bladder
comprises  approximately  0.5%  of  all  bladder
malignancies.15 The mean age of presentation
is 66.1 years and the male to female ratio is
3.6:1.14 Since  1981,  when  Cramer  et  al.
described the first case of bladder SCC, more
than  200  cases  have  been  reported  so  far.13
Weng et al. earlier in 1977 described the first
case  of  prostate  SCC.17 As  their  pulmonary
counterpart, they share the features of aggres-
siveness,  invasiveness,  early  metastasis  and
poor prognosis.18
Several  theories  have  been  proposed  to
explain  the  histogenesis  of  the  extra  pul-
monary  SCC,14 but  the  theory  of  malignant
transformation of neuroendocrine amine pre-
cursor uptake and decarboxylation (APUD) cell
systems seems to prevail.19 Other studies sug-
gest  the  malignant  transformation  of  poorly
defined submucosal or musculris propria cells
and the metaplasia of high grade transitional
cell carcinoma.20
The bladder SCC should be suspected when
the tumor displays an aggressive behavior and
advanced stage presentation. Hematuria, uri-
nary  retention,  dysuria,  poor  stream  urine,
suprapubic or flank pain and rarely paraneo-
plastic syndromes as hypocalcaemia, hypopho  -
sphatemia, Cushing syndrome and elevated ʱ-
fetoprotein  are  the  usual  presenting  symp-
toms.14 The definite diagnosis is by immuno-
histochemistry of the resected tissue although
imaging modalities (US, CT) should raise a
suspicion  mainly  by  the  high  volume  mass.
Under direct vision these tumors are usually
polypoid, ulcerated and large in size from 4-10
cm, and they present on lateral walls (54%),
posterior  wall  (20%),  trigone  (10%),  dome
(8%) and anterior wall (8%).21 Immunohisto  -
chemistry  techniques  such  as  chromogranin
staining, neural adhesion molecule and synap-
tophycin  are  helpful  since  cancerous  cells
express markers of neuroendocrine differenti-
ation.22 A metastatic disease from pulmonary
Figure  1.  A  computer  tomografy  image
showing the lesion at the left lateral blad-
der  wall  after  administration  of  contrast
material.
Figure 2. The microcytic cellular pattern,
typical for small cell carcinoma histological
diagnosis.
Figure 3. The histological specimen shows
an area which is occupied by the SCC at
the left and by the typical adenocarcinoma
at the right.
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or extra pulmonary SCC (including prostatic
SCC) should be excluded. 
The treatment of bladder SCC is still a mat-
ter of concern since there are no prospective
studies with big patient series. Most authors
agree that a threefold therapy including sur-
gery, chemotherapy (neoadjuvant or adjuvant)
and radiotherapy should be offered, since blad-
der SCC is already a systemic disease at the
time of diagnosis.23 Galanis et al., proved that a
combination  of  chemotherapy  and  radiation
could  be  as  effective  as  surgery  in  patients
with limited disease.24 Choong et al., in a 44
patient series, concluded that all patients with
bladder  SCC  should  undergo  radical  cysto-
prostatectomy  except  those  with  metastatic
disease (M1), in which systemic chemothera-
py  is  indicated.25 They  concluded  also  that
patients  with  stage  III  &  IV  should  receive
adjuvant platinum based chemotherapy. Siefke
et al, in a larger study of 88 patients studied
the  neoadjuvant  chemotherapy  in  patients
with bladder SCC prior to radical cystectomy,
in order to downstage the tumor. [26] They
found that patients treated with initial cystec-
tomy  median  cancer  survival  (CSS)  was  23
months, with 36% disease-free rate at 5 years,
while  those  who  received  preoperative
chemotherapy  had  CSS  that  couldn’t  been
reached and a 78% disease free rate at 5 years.
Moreover, they reported that no cancer related
death  occur  among  patients  with  disease
downstages to pT2 or less. We use a 3 14-day
cycles of MVAC as proposed by Bamias et al.6
The therapy was well tolerated with few side
effects. In case of local relapse or in develop-
ment of distant metastasis we will offer a com-
bination  of  chemotherapy  and  radiotherapy.
We strongly believe that patients who present
with bladder SCC of limited disease should be
treated  by  radical  surgery  and  adjuvant
chemotherapy and those patients who present
with  an  advanced  stage  of  disease  (M+)  a
combination therapy of surgery, chemotherapy
and radiotherapy is the treatment of choice. 
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